Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio
Trestle Biotherapeutics: funding and company profile
Bioengineered therapies for Kidney Disease
Key Investors
- Sahin Boydas (Angel)
Funding Timeline
| Round | Raised | Date |
|---|---|---|
| Biz Plan Competition | $1M | 2023-06-12 |
| Seed | $125K | 2021-01-05 |
Total raised: $1M
Why I Invested
As an angel investor in 234 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. Trestle Biotherapeutics stood out in the Biotech space.